Topic outline

  • General

  • Friday 2nd December


    Friday 2nd December   

    09.00:  Welcome

    Session 1:  Innovation

    Chairs: Noreen Gleeson, Matt Hewitt

    09.15: “Surgical innovation” Prof. Ronan Cahill, Professor of Surgery, Mater Misericordiae University Hospital, UCD

    09.45: “Medical Device Design at UCD - Minimally Invasive Access and Therapeutic Delivery Devices”  Dr Eoin O’Cearbhall – Biomedical Engineering, UCD

    10.15: “Lessons in the metastatic cascade” Prof. John O’Leary, Professor of Pathology, TCD

    Coffee: 10.45-11.05

    Session 2: Surgical management peritoneal carcinomatosis

    Chairs: Ian Harley, Donal Brennan

    Sponsored by 

    11.05  “Predicting optimal cytoreduction “.Prof Michael Birrer, Professor of Medicine at Harvard Medical School and Director of Gillette Center for Gynecologic Oncology at Massachusetts General Hospital. 

    11.50: “Lessons learned from CRS and HIPEC for disseminated peritoneal malignancy – the Basingstoke experience” Mr Brendan Moran, Director of Peritoneal Malignancy Institute, BasingstokeSession 2:  Predicting therapeutic response

    Lunch 12.35 – 13.15


    CPD points applied for (RCPI)



    13.15-14.00 – Session Sponsored by     

    “Current status of intraperitoneal chemotherapy for ovarian cancer post GOG 252”

    Prof Bradley Monk, Director of the Division of Gynecologic Oncology, Creighton University School of Medicine, St. Joseph’s Hospital and Medical Centre Phoenix, Arizona


    Session 3:  Survivorship

    Chairs: Charles Gilham, Dearbhaille O’ Donnell

    14.00: “Weight loss – lessons learned from bariatric surgery” Prof. Carel LeRoux, Professor of Pathology, UCD.

    14.30: “Exercise in BRCA mutation carriers”  Dr David Gallagher, National Lead for Cancer Genetics (SJH / TCD)

    15.00: “Pelvic Radiation Disease: progress in the management of GI consequences of treatment”  Dr Jervoise Andreyev , Consultant Gastroenterologist in Pelvic Radiation Disease , Royal Marsden


    Coffee :15.45-16.05

    Session 4:  Thrombosis risk in Gynaecological Malignancy

    Sponsored by:           

    16.05: “VTE  in gynae cancer - who is at risk and when?”

     Dr Feras Abu Saadeh, Consultant Gynaecological Oncologist, SJH.

    16.30: “Guidelines for VTE prophylaxis in gynae cancer.”  Dr. Kevin Ryan Haematologist SJH

    17.05: “Can we predict VTE in gynae cancer?”  Dr Lucy Norris, Dept of Obstetrics and Gynaecology, TCD



    17:30 – 18.30: Science Foundation Ireland Networking workshop

    19.00:  Drinks reception + conference dinner in National Gallery of Ireland


    CPD points applied for (RCPI)

    Platinum Sponsors:          OLYMPUS LOGO

    Gold Sponsor: 

  • Saturday 3rd December

    Saturday 3rd December

    *Session 5:  Submitted abstracts      *Session 6: Patient and Public Involvement Workshop
    09.00-10.30: 6 x 12 minute talks


           09.30-12.30:  Georgian Rooms, National Gallery of Ireland

    Chairs: Michael O’Leary, Ruaidhri McVey

    Note:  Session 5 and 6 are parallel sessions

    Coffee: 10.30-11.00


    Session 7:  Predicting therapeutic response 

    Chairs: Donal Brennan, Cathy Kelly

    11.00: “Novel targets in epithelial ovarian cancer” Prof. Michael Birrer, Professor of Medicine at Harvard Medical School and Director of Gillette Center for Gynecologic Oncology at Massachusetts General Hospital.

    11.45 “FKBPL – from the bench to phase 1 trial”  Prof. Tracy Robson,  Professor of Cancer Therapeutics, RCSI

    12.15: “DNA damage response assay in High Grade Serous Ovarian Cancer“ Prof. Richard Kennedy, McClay Professor of Medical Oncology, Queen's University Belfast.


    Lunch: 12.45 – 13.15


    Session 8: ISGO AGM – “The future of gynaecological oncology in Ireland”


    13.30 -15.30

    Surgical, Medical Oncology, Radiation Oncology, Palliative Care, Patient representative, Research, Allied health


    15.30 – close of meeting


  • Patient and Significant-Other Sessions

    • Meet the Event Organisers